Demonstration of dose-response of flurbiprofen lozenge for sore throat

Schachtel, B.; Homan, Harvey D.; Gibb, I.A.; Christian, J

doi:10.1016/s0009-9236(99)80002-2

Cited by 2 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Variable results were obtained with the flurbiprofen 12.5 mg lozenges; the small sample size of this dosage group probably contributed to these findings. Overall the results for flurbiprofen 12.5 mg between this and a previous study 20 were consistent, providing assurance that the method is validated and, therefore, that the 8.75 mg results are relevant.…”

Section: Discussionsupporting

confidence: 84%

“…The demulcent effect can decrease the sensitivity of the sore throat model, and trials using lozenge formulations are associated with high placebo responses, as a non‐medicated lozenge is not a true placebo. This placebo effect may account for the borderline statistical significance for the primary efficacy variable, TOTPAR 15–120 min , although this variable demonstrated statistical significance compared with placebo in other clinical studies of the flurbiprofen lozenge 20,28 . In general, the results from this study are in accordance with other trials and overall strongly demonstrate efficacy for the flurbiprofen lozenge.…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Relief of Sore Throat With the Anti‐inflammatory Throat Lozenge Flurbiprofen 8.75 Mg: A Randomised, Double‐blind, Placebo‐controlled Study of Efficacy and Safety

Watson¹,

Ws²,

Christian³

et al. 2000

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYIn this double‐blind study, 301 patients with subjective and objective signs of sore throat were randomly assigned to flurbiprofen 8.75 mg (n=129), flurbiprofen 12.5 mg (n=43) or placebo (demulcent lozenge without active drug [n=129]). Efficacy was assessed by changes in subjective rating scales primarily after a single dose and also over a 4‐day period. Flurbiprofen 8.75 mg was superior to placebo in a number of efficacy parameters, notably throat soreness. Throat soreness was significantly reduced after 15 minutes (p<0.05), with effects sustained for at least 2 hours (p<0.05). Multiple dosing with flurbiprofen 8.75 mg lozenges continued to provide effective symptomatic relief over the 4‐day treatment period. The small sample size was considered contributory to the variable results obtained with flurbiprofen 12.5 mg lozenges, but overall these were not inconsistent with previous trials. Both treatments were tolerated well. Flurbiprofen 8.75 mg lozenges provide an effective and well tolerated treatment for sore throat.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 82%

Relief of Sore Throat With the Anti‐inflammatory Throat Lozenge Flurbiprofen 8.75 Mg: A Randomised, Double‐blind, Placebo‐controlled Study of Efficacy and Safety

Watson¹,

Ws²,

Christian³

et al. 2000

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

“…This double‐blind, randomised study used rating scales associated with the sore throat pain model to compare the efficacy of flurbiprofen 8.75 mg and placebo. These rating scales have previously been used successfully to assess the analgesic activity of flurbiprofen lozenges 6–8 …”

Section: Discussionmentioning

confidence: 99%

“…A new lozenge containing the non‐steroidal anti‐inflammatory drug (NSAID) flurbiprofen has been developed to relieve the pain and inflammation associated with sore throat. Flurbiprofen lozenges have been shown in clinical trials to provide relief from the symptoms of sore throat 6–8 …”

mentioning

confidence: 99%

See 1 more Smart Citation

Multidose Flurbiprofen 8.75 Mg Lozenges in the Treatment of Sore Throat: A Randomised, Double‐blind, Placebo‐controlled Study in Uk General Practice Centres

Blagden¹,

Christian²,

Miller³

et al. 2002

Int J Clinical Practice

Self Cite

View full text Add to dashboard Cite

SUMMARYThe flurbiprofen 8.75 mg lozenge is a novel formulation that combines a demulcent effect with the analgesic activity of a non‐steroidal anti‐inflammatory drug. Previous controlled clinical studies have demonstrated the single‐ and multi‐dose efficacy of these lozenges over placebo. The current study reflected the treatment of sore throat in general practice, investigating multiple dose efficacy where patients also had access to concomitant antibiotics and rescue medication. The efficacy of flurbiprofen 8.75 mg lozenge over placebo was confirmed: there was a significant difference in pain relief obtained from flurbiprofen 8.75 mg versus placebo, along with a significant reduction of difficulty in swallowing from the time of first assessment and significantly greater reductions in throat soreness and difficulty in swallowing throughout the study period. Additionally, significant benefit over placebo was demonstrated where concomitant antibiotic use was introduced, indicating that flurbiprofen 8.75 mg lozenges can be co‐administered when antibiotic therapy is appropriate. No significant safety issues were identified.

show abstract

Demonstration of dose-response of flurbiprofen lozenge for sore throat

Abstract: Clinical Pharmacology & Therapeutics (1999) 65, 117–117; doi:

Cited by 2 publications

References 0 publications

Relief of Sore Throat With the Anti‐inflammatory Throat Lozenge Flurbiprofen 8.75 Mg: A Randomised, Double‐blind, Placebo‐controlled Study of Efficacy and Safety

Relief of Sore Throat With the Anti‐inflammatory Throat Lozenge Flurbiprofen 8.75 Mg: A Randomised, Double‐blind, Placebo‐controlled Study of Efficacy and Safety

Multidose Flurbiprofen 8.75 Mg Lozenges in the Treatment of Sore Throat: A Randomised, Double‐blind, Placebo‐controlled Study in Uk General Practice Centres

Contact Info

Product

Resources

About